The molecular basis for the weaker activity of T was investigated by determining T-bound ligand binding domain crystal structures of wild-type AR and a prostate cancer somatic mutant complexed with the AR FXXLF or coactivator LXXLL peptide.
In prostate cancer, somaticAR mutations in AF2 or near the bound ligand slow androgen dissociation and increase AR stabilization and coactivator recruitment.